Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyZacks Investment Research · Oct 13, 2026
New Strong Buy Stocks for October 9thZacks Investment Research · Oct 9, 2026
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to AnalystsDefense World · Sep 30, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)GlobeNewsWire · Sep 24, 2026
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?GuruFocus · Sep 9, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)GlobeNewsWire · Sep 9, 2026Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 31, 2026 | -$0.28 | $0.08 | Beat |
| May 7, 2026 | -$0.32 | -$0.28 | Beat |
| Mar 27, 2026 | -$0.34 | -$0.20 | Beat |
| Nov 4, 2025 | -$0.39 | -$0.36 | Beat |
| Aug 14, 2025 | -$0.50 | -$0.40 | Beat |
| May 8, 2025 | -$0.44 | -$0.40 | Beat |